Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28011577 | 0.97 | KCNN4 (0.49) | CYP2A6DPP4KCNN4LMNATSHR | |
| Methylene Chloride SCHEMBL27731621 | 0.93 | DPP4 (0.47) | CYP2A6DPP4KCNN4LMNATSHR | |
| SCHEMBL29883244 | 0.83 | CYP2A6 (0.67) | CYP2A6DPP4LMNATSHRNPC1 | |
| SCHEMBL29547174 | 0.83 | ACHE (0.47) | NPC1RAB9ASMN1; SMN2PTPRCKMT2A | |
| SCHEMBL29802156 | 0.83 | CYP2A6 (0.67) | CYP2A6DPP4LMNATSHRNPC1 | |
| SCHEMBL197834 | 0.83 | ACHE (0.47) | NPC1RAB9ASMN1; SMN2PTPRCKMT2A | |
| SCHEMBL671133 | 0.83 | CYP2A6 (0.67) | CYP2A6DPP4LMNATSHRNPC1 | |
| Ammonia Solution, Strong SCHEMBL735046 | 0.80 | CYP2A6 (0.63) | CYP2A6DPP4LMNATSHRNPC1 | |
| SCHEMBL30389980 | 0.80 | PTPRC (0.48) | KCNN4LMNANPC1RAB9ASMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL10700223 | 0.80 | ACHE (0.45) | NPC1RAB9ASMN1; SMN2PTPRCKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5540838-A | Stimulation of microbial para-dechlorination of polychlorinated biphenyls | GENERAL ELECTRIC COMPANY (US) | 1996-07-30 | — | — | US | claimed |
| EP-3143026-B1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11447465-B2 | Pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20200237737-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-07-30 | — | — | US | disclosed |
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10383863-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-20190134012-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2019-05-09 | — | — | US | disclosed |
| US-10188638-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| CN-109071500-A | Process for preparing 5-hydroxyalkyl-substituted 1-phenyl-1, 2, 4-triazole derivatives | 拜耳制药股份公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-08-24 | — | — | US | disclosed |
| US-9688689-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| WO-2017035418-A1 | DISUBSTITUTED COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| CN-101218223-A | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH CORP (US) | 2008-07-09 | — | — | CN | disclosed |
| US-5540838-A | Stimulation of microbial para-dechlorination of polychlorinated biphenyls | GENERAL ELECTRIC COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| US-5540838-A | Stimulation of microbial para-dechlorination of polychlorinated biphenyls | GENERAL ELECTRIC COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CYP2A6 3060/4885DPP4 2412/4885KCNN4 4427/4885 |
| US-10188638-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | CYP2A6 2777/4885DPP4 2098/4885KCNN4 4709/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CYP2A6 207/4885DPP4 826/4885KCNN4 2391/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CYP2A6 207/4885DPP4 826/4885KCNN4 2391/4885 |
| US-20200237737-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | CYP2A6 2777/4885DPP4 2098/4885KCNN4 4709/4885 |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | CYP2A6 2777/4885DPP4 2098/4885KCNN4 4709/4885 |
| US-10383863-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | CYP2A6 2777/4885DPP4 2098/4885KCNN4 4709/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CYP2A6 1136/4885DPP4 537/4885KCNN4 1586/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CYP2A6 4045/4885DPP4 1633/4885KCNN4 3863/4885 |
| US-11447465-B2 | Pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CYP2A6 1136/4885DPP4 537/4885KCNN4 1586/4885 |
| US-10660881-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | CYP2A6 2777/4885DPP4 2098/4885KCNN4 4709/4885 |
| US-20190134012-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | CYP2A6 2777/4885DPP4 2098/4885KCNN4 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.